Based on a strategy of delivering a broad range of assays for use on the Celerus Wave System, Celerus Diagnostics has launced the Wave Direct Immunofluorescence (IF) assay.
The Wave Direct IF assay provides clinical and research pathology labs with the ability to perform rapid, direct immunofluorescence on the Wave System. Lusk said. Already able to provide Rapid IHC, additional assays, such as Direct IF, make the Celerus Wave System an even more capable staining platform.
Direct IF is used in a number of clinical applications in anatomic pathology laboratories. Among them, direct IF assays provide pathologists with adjunctive information to aid in the diagnosis of renal disease. By standardizing this assay and reducing turnaround times, the Celerus Wave System delivers the flexibility sanatomic pathology labs require to improve patient care.
Celerus Diagnostics introduced Rapid IHC with its Wave System in 2008. In addition to standard immunohistochemistry applications, breast, neuro, and Mohs surgeons also benefit significantly from intraoperative results made possible in just 15 minutes.
